Expert opinion
Watch our leading breast cancer experts share their thoughts on:
- the clinical utility of CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer
- the key considerations when selecting the right CDK4/6 inhibitor for your patient
- optimal management of patients treated with CDK4/6 inhibitors
- commentary on the use of CDK4/6 inhibitors in the COVID-19 era
Welcome to our webinar titled ‘Managing risk of recurrence in early breast cancer - What’s on the horizon?’
See below for the most intriguing and up to date talks on the evolving treatment landscape in early breast cancer
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Roundtable Event 2020: CDK4/6 inhibitors and patient management
In the HR+/HER2- metastatic breast cancer setting, healthcare professionals have moved away from first-line chemotherapy towards CDK4/6 inhibitors (palbociclib, ribociclib and abemaciclib) as the new standard of care.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Medical expert interviews
Here, you can find the full medical expert interviews on CDK4/6 inhibitors for treating HR+/HER2- metastatic breast cancer with our breast cancer experts, Dr Gregory Vidal, Dr Laura Spring and Dr Alistair Ring.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Medical expert biographies
Dr Gregory Vidal, MD, PhD, is a Medical Oncologist at West Cancer Center and Research Institute and Assistant Professor at the University of Tennessee Health Science Center. Dr Vidal trained as a clinical researcher at the University of Stanford, taking part in research led by leading medical researchers. The aim of his research then, and now, is to discover and develop safe and effective treatments for breast cancer. Dr Vidal is the recipient of multiple awards and he has authored and co-authored numerous research articles in journals including the New England Journal of Medicine, Lancet Oncology and Nature Communications.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
of interest
are looking at
saved
next event
Developed by EPG Health for Medthority. This content has been developed independently of the sponsor Eli Lilly, who have had no editorial input into the content. EPG Health received unrestricted educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.